{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:13:31Z","timestamp":1787170411527,"version":"build-2736575974"},"reference-count":194,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-04091-4","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:44:52Z","timestamp":1765007092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Harnessing miR-145 in NSCLC: mechanistic roles, diagnostic-prognostic utility, and therapeutic potential"],"prefix":"10.1186","volume":"26","author":[{"given":"Safa","family":"Tahmasebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davar","family":"Amani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmaeil","family":"Mortaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"issue":"8","key":"4091_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.35128","volume":"130","author":"TB Kratzer","year":"2024","unstructured":"Kratzer TB, et al. Lung cancer statistics, 2023. Cancer. 2024;130(8):1330\u201348.","journal-title":"Cancer"},{"issue":"1","key":"4091_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","volume":"44","author":"D Miao","year":"2024","unstructured":"Miao D, et al. Management of locally advanced non-small cell lung cancer: state of the Art and future directions. Cancer Commun (Lond). 2024;44(1):23\u201346.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"4091_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13353-023-00750-2","volume":"64","author":"M Frydrychowicz","year":"2023","unstructured":"Frydrychowicz M, et al. MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy. J Appl Genet. 2023;64(3):459\u201377.","journal-title":"J Appl Genet"},{"issue":"3","key":"4091_CR4","doi-asserted-by":"publisher","first-page":"230127","DOI":"10.1183\/20734735.0127-2023","volume":"20","author":"DL T\u00e1rnoki","year":"2024","unstructured":"T\u00e1rnoki DL, et al. Lung imaging methods: indications, strengths and limitations. Breathe (Sheff). 2024;20(3):230127.","journal-title":"Breathe (Sheff)"},{"issue":"1","key":"4091_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","volume":"203","author":"H Jeon","year":"2025","unstructured":"Jeon H, et al. Update 2025: management of Non\u2013Small-Cell lung cancer. Lung. 2025;203(1):53.","journal-title":"Lung"},{"key":"4091_CR6","doi-asserted-by":"publisher","first-page":"115891","DOI":"10.1016\/j.biopha.2023.115891","volume":"169","author":"Y Li","year":"2023","unstructured":"Li Y, Yan B, He S. Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023;169:115891.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4091_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281\u201397.","journal-title":"Cell"},{"issue":"30","key":"4091_CR8","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, et al. Circulating MicroRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"4091_CR9","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jcmm.12358","volume":"18","author":"SY Cui","year":"2014","unstructured":"Cui SY, Wang R, Chen LB. MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014;18(10):1913\u201326.","journal-title":"J Cell Mol Med"},{"key":"4091_CR10","doi-asserted-by":"publisher","unstructured":"Tahmasebi, S., Amani, D., Salimi, B., Adcock, I. M., & Mortaz, E. (2025). LncRNA-Mediated miR-145 Sponging Drives FN1 and CCND1 Expression: Prognostic and Therapeutic Targets in NSCLC. Biomolecules, 15(11), 1564. https:\/\/doi.org\/10.3390\/biom15111564","DOI":"10.3390\/biom15111564"},{"issue":"4","key":"4091_CR11","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.3892\/mmr.2014.3036","volume":"11","author":"DJ Ling","year":"2015","unstructured":"Ling DJ, et al. MicroRNA-145 inhibits lung cancer cell metastasis. Mol Med Rep. 2015;11(4):3108\u201314.","journal-title":"Mol Med Rep"},{"key":"4091_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/CMAR.S191696","volume":"11","author":"D Ye","year":"2019","unstructured":"Ye D, Shen Z, Zhou S. Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. Cancer Manag Res. 2019;11:969\u201379.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"4091_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3892\/ol.2021.13130","volume":"23","author":"SL Geater","year":"2022","unstructured":"Geater SL, et al. Diagnostic and prognostic value of serum miR-145 and vascular endothelial growth factor in non-small cell lung cancer. Oncol Lett. 2022;23(1):12.","journal-title":"Oncol Lett"},{"issue":"1","key":"4091_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1756-9966-29-151","volume":"29","author":"Z Chen","year":"2010","unstructured":"Chen Z, et al. MiRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010;29(1):151.","journal-title":"J Exp Clin Cancer Res"},{"key":"4091_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210022","author":"WC Cho","year":"2023","unstructured":"Cho WC, et al. MiR-145 as a potential biomarker and therapeutic target in patients with non-small cell lung cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241210022.","journal-title":"Int J Mol Sci"},{"key":"4091_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ncrna.2024.11.001","volume":"11","author":"MS Rahman","year":"2025","unstructured":"Rahman MS, et al. Dr. Jekyll or Mr. Hyde: the multifaceted roles of miR-145-5p in human health and disease. Non-coding RNA Res. 2025;11:22\u201337.","journal-title":"Non-coding RNA Res"},{"key":"4091_CR17","doi-asserted-by":"publisher","first-page":"155222","DOI":"10.1016\/j.prp.2024.155222","volume":"256","author":"S Singh","year":"2024","unstructured":"Singh S, et al. Emerging role of tumor suppressing MicroRNAs as therapeutics in managing non-small cell lung cancer. Pathol Res Pract. 2024;256:155222.","journal-title":"Pathol Res Pract"},{"issue":"8","key":"4091_CR18","doi-asserted-by":"publisher","first-page":"e32899","DOI":"10.1097\/MD.0000000000032899","volume":"102","author":"Y Alduais","year":"2023","unstructured":"Alduais Y, et al. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Med (Baltim). 2023;102(8):e32899.","journal-title":"Med (Baltim)"},{"issue":"6","key":"4091_CR19","first-page":"1747","volume":"25","author":"R Yin","year":"2011","unstructured":"Yin R, et al. microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep. 2011;25(6):1747\u201354.","journal-title":"Oncol Rep"},{"issue":"9","key":"4091_CR20","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.31557\/APJCP.2019.20.9.2781","volume":"20","author":"J Amri","year":"2019","unstructured":"Amri J, et al. Targeting epidermal growth factor receptor by MiRNA-145 inhibits cell growth and sensitizes NSCLC cells to erlotinib. Asian Pac J Cancer Prev. 2019;20(9):2781\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"4091_CR21","first-page":"6923","volume":"14","author":"Y Chang","year":"2017","unstructured":"Chang Y, et al. miR-145-5p inhibits epithelial-mesenchymal transition via the JNK signaling pathway by targeting MAP3K1 in non-small cell lung cancer cells. Oncol Lett. 2017;14(6):6923\u20138.","journal-title":"Oncol Lett"},{"key":"4091_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.abb.2018.03.018","volume":"645","author":"Y Chen","year":"2018","unstructured":"Chen Y, et al. Long non-coding RNA ROR promotes radioresistance in hepatocelluar carcinoma cells by acting as a CeRNA for microRNA-145 to regulate RAD18 expression. Arch Biochem Biophys. 2018;645:117\u201325.","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"4091_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1724600820967124","volume":"35","author":"S Tao","year":"2020","unstructured":"Tao S, et al. Circulating microRNA-145 as a diagnostic biomarker for non-small-cell lung cancer: A systemic review and meta-analysis. Int J Biol Mark. 2020;35(4):51\u201360.","journal-title":"Int J Biol Mark"},{"issue":"2","key":"4091_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jconrel.2012.01.014","volume":"159","author":"G-Y Chiou","year":"2012","unstructured":"Chiou G-Y, et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial\u2013mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Controlled Release. 2012;159(2):240\u201350.","journal-title":"J Controlled Release"},{"issue":"1","key":"4091_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024;9(1):170.","journal-title":"Signal Transduct Target Ther"},{"key":"4091_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020276","author":"CE Condrat","year":"2020","unstructured":"Condrat CE, et al. Mirnas as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9020276.","journal-title":"Cells"},{"key":"4091_CR27","doi-asserted-by":"publisher","first-page":"117473","DOI":"10.1016\/j.lfs.2020.117473","volume":"248","author":"MMH Sohel","year":"2020","unstructured":"Sohel MMH. Circulating MicroRNAs as biomarkers in cancer diagnosis. Life Sci. 2020;248:117473.","journal-title":"Life Sci"},{"issue":"1","key":"4091_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/CBM-210223","volume":"35","author":"S Takizawa","year":"2022","unstructured":"Takizawa S, Matsuzaki J, Ochiya T. Circulating micrornas: challenges with their use as liquid biopsy biomarkers. Cancer Biomark. 2022;35(1):1\u20139.","journal-title":"Cancer Biomark"},{"key":"4091_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3389\/fchem.2019.00815","volume":"7","author":"J Cacheux","year":"2019","unstructured":"Cacheux J, et al. Technological challenges and future issues for the detection of Circulating MicroRNAs in patients with cancer. Front Chem. 2019;7:815.","journal-title":"Front Chem"},{"issue":"3","key":"4091_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jcmm.12236","volume":"18","author":"L Moldovan","year":"2014","unstructured":"Moldovan L, et al. Methodological challenges in utilizing MiRNAs as Circulating biomarkers. J Cell Mol Med. 2014;18(3):371\u201390.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"4091_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. Microrna therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203\u201322.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4091_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","volume":"44","author":"MTD Martino","year":"2025","unstructured":"Martino MTD, Tagliaferri P, Tassone P. Microrna in cancer therapy: breakthroughs and challenges in early clinical applications. J Exp Clin Cancer Res. 2025;44(1):126.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"4091_CR33","first-page":"3247","volume":"17","author":"A Sui","year":"2019","unstructured":"Sui A, Zhang X, Zhu Q. Diagnostic value of serum miR197 and miR145 in non-small cell lung cancer. Oncol Lett. 2019;17(3):3247\u201352.","journal-title":"Oncol Lett"},{"issue":"12","key":"4091_CR34","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.ejca.2009.04.039","volume":"45","author":"WC Cho","year":"2009","unstructured":"Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009;45(12):2197\u2013206.","journal-title":"Eur J Cancer"},{"issue":"44","key":"4091_CR35","doi-asserted-by":"publisher","first-page":"72084","DOI":"10.18632\/oncotarget.12290","volume":"7","author":"H Mataki","year":"2016","unstructured":"Mataki H, et al. Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. Oncotarget. 2016;7(44):72084\u201398.","journal-title":"Oncotarget"},{"issue":"3","key":"4091_CR36","doi-asserted-by":"publisher","first-page":"101042831769168","DOI":"10.1177\/1010428317691683","volume":"39","author":"T-q Gan","year":"2017","unstructured":"Gan T-q, et al. Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data. Tumor Biology. 2017;39(3):1010428317691683.","journal-title":"Tumor Biology"},{"key":"4091_CR37","doi-asserted-by":"publisher","DOI":"10.3892\/or.2025.8872","author":"Z Chen","year":"2025","unstructured":"Chen Z, Qin Y. Role of miRNA\u2011145\u20115p in cancer (Review). Oncol Rep. 2025. https:\/\/doi.org\/10.3892\/or.2025.8872.","journal-title":"Oncol Rep"},{"issue":"1","key":"4091_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4161\/rna.8.1.14259","volume":"8","author":"WC Cho","year":"2011","unstructured":"Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011;8(1):125\u201331.","journal-title":"RNA Biol"},{"issue":"3","key":"4091_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.cbi.2010.01.025","volume":"184","author":"M Zhong","year":"2010","unstructured":"Zhong M, et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem Biol Interact. 2010;184(3):431\u20138.","journal-title":"Chem Biol Interact"},{"key":"4091_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13148-017-0380-0","volume":"9","author":"E Evanno","year":"2017","unstructured":"Evanno E, et al. Tri-methylation of H3K79 is decreased in TGF-\u03b21-induced epithelial-to-mesenchymal transition in lung cancer. Clin Epigenetics. 2017;9:80.","journal-title":"Clin Epigenetics"},{"key":"4091_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.canlet.2018.01.036","volume":"418","author":"C Li","year":"2018","unstructured":"Li C, et al. Long non-coding RNA XIST promotes TGF-\u03b2-induced epithelial-mesenchymal transition by regulating miR-367\/141-ZEB2 axis in non-small-cell lung cancer. Cancer Lett. 2018;418:185\u201395.","journal-title":"Cancer Lett"},{"issue":"1","key":"4091_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12935-018-0601-4","volume":"18","author":"Q Yin","year":"2018","unstructured":"Yin Q, et al. MiR-145 and miR-497 suppress TGF-\u03b2-induced epithelial\u2013mesenchymal transition of non-small cell lung cancer by targeting MTDH. Cancer Cell Int. 2018;18(1):105.","journal-title":"Cancer Cell Int"},{"key":"4091_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2016.04.017","volume":"97","author":"H Hu","year":"2016","unstructured":"Hu H, et al. MiR-145 and miR-203 represses TGF-\u03b2-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells. Lung Cancer. 2016;97:87\u201394.","journal-title":"Lung Cancer"},{"key":"4091_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080840","author":"AQ Khan","year":"2019","unstructured":"Khan AQ, et al. Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8080840.","journal-title":"Cells"},{"issue":"1","key":"4091_CR45","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1186\/s12885-024-12523-z","volume":"24","author":"W Yan","year":"2024","unstructured":"Yan W, et al. Bone marrow mesenchymal stem cells-derived exosomal miR-145-5p reduced non-small cell lung cancer cell progression by targeting SOX9. BMC Cancer. 2024;24(1):883.","journal-title":"BMC Cancer"},{"issue":"1","key":"4091_CR46","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12943-024-02183-9","volume":"23","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication. Mol Cancer. 2024;23(1):268.","journal-title":"Mol Cancer"},{"issue":"1","key":"4091_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-022-01365-6","volume":"15","author":"H Wang","year":"2022","unstructured":"Wang H, et al. The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy. J Hematol Oncol. 2022;15(1):140.","journal-title":"J Hematol Oncol"},{"key":"4091_CR48","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.biopha.2018.12.094","volume":"111","author":"N Sadeghiyeh","year":"2019","unstructured":"Sadeghiyeh N, et al. MicroRNA-145 replacement effect on growth and migration Inhibition in lung cancer cell line. Biomed Pharmacother. 2019;111:460\u20137.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"4091_CR49","first-page":"4337","volume":"15","author":"Y Pan","year":"2018","unstructured":"Pan Y, et al. MiR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX\/BCL-2 ratio and the caspase-3 cascade. Oncol Lett. 2018;15(4):4337\u201343.","journal-title":"Oncol Lett"},{"issue":"1","key":"4091_CR50","first-page":"257","volume":"53","author":"K Liu","year":"2018","unstructured":"Liu K, et al. miR\u2013145 inhibits human non\u2013small-cell lung cancer growth by dual-targeting RIOK2 and NOB1. Int J Oncol. 2018;53(1):257\u201365.","journal-title":"Int J Oncol"},{"issue":"7519","key":"4091_CR51","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559\u201363.","journal-title":"Nature"},{"key":"4091_CR52","doi-asserted-by":"publisher","first-page":"217639","DOI":"10.1016\/j.canlet.2025.217639","volume":"620","author":"J Li","year":"2025","unstructured":"Li J, et al. CircRUNX1 enhances the Warburg effect and immune evasion in non-small cell lung cancer through the miR-145\/HK2 pathway. Cancer Lett. 2025;620:217639.","journal-title":"Cancer Lett"},{"key":"4091_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2018.12.027","volume":"107","author":"Y Huang","year":"2019","unstructured":"Huang Y, et al. IL-16 regulates macrophage polarization as a target gene of mir-145-3. Mol Immunol. 2019;107:1\u20139.","journal-title":"Mol Immunol"},{"issue":"7","key":"4091_CR54","doi-asserted-by":"publisher","first-page":"11115","DOI":"10.1002\/jcb.28388","volume":"120","author":"C Jin","year":"2019","unstructured":"Jin C, et al. miR-145-5p inhibits tumor occurrence and metastasis through the NF-\u03baB signaling pathway by targeting TLR4 in malignant melanoma. J Cell Biochem. 2019;120(7):11115\u201326.","journal-title":"J Cell Biochem"},{"issue":"1","key":"4091_CR55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12860-022-00430-9","volume":"23","author":"CH Yuan","year":"2022","unstructured":"Yuan CH, et al. MicroRNA-145-5p modulates Kr\u00fcppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma. BMC Mol Cell Biol. 2022;23(1):28.","journal-title":"BMC Mol Cell Biol"},{"key":"4091_CR56","doi-asserted-by":"publisher","first-page":"624725","DOI":"10.3389\/fimmu.2021.624725","volume":"12","author":"Y Xing","year":"2021","unstructured":"Xing Y, et al. Tumor immune microenvironment and its related miRNAs in tumor progression. Front Immunol. 2021;12:624725.","journal-title":"Front Immunol"},{"issue":"6282","key":"4091_CR57","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227\u201331.","journal-title":"Science"},{"key":"4091_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lungcan.2017.06.006","volume":"110","author":"EY Kim","year":"2017","unstructured":"Kim EY, et al. MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer. 2017;110:63\u20137.","journal-title":"Lung Cancer"},{"issue":"1","key":"4091_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/cei.13406","volume":"200","author":"Q Sheng","year":"2020","unstructured":"Sheng Q, et al. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Clin Exp Immunol. 2020;200(1):45\u201352.","journal-title":"Clin Exp Immunol"},{"key":"4091_CR60","doi-asserted-by":"publisher","first-page":"e2400790","DOI":"10.1200\/PO-24-00790","volume":"9","author":"MV Chiaruttini","year":"2025","unstructured":"Chiaruttini MV, et al. Tracking the response to immunotherapy: blood microRNA dynamics in patients with advanced non-small cell lung cancer. JCO Precis Oncol. 2025;9:e2400790.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"4091_CR61","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1038\/s41467-018-05023-9","volume":"9","author":"H Ishii","year":"2018","unstructured":"Ishii H, et al. miR-130a and miR-145 reprogram Gr-1(+)CD11b(+) myeloid cells and inhibit tumor metastasis through improved host immunity. Nat Commun. 2018;9(1):2611.","journal-title":"Nat Commun"},{"key":"4091_CR62","doi-asserted-by":"publisher","first-page":"1089320","DOI":"10.3389\/fonc.2022.1089320","volume":"12","author":"N Samarth","year":"2022","unstructured":"Samarth N, Gulhane P, Singh S. Immunoregulatory framework and the role of MiRNA in the pathogenesis of NSCLC - A systematic review. Front Oncol. 2022;12:1089320.","journal-title":"Front Oncol"},{"issue":"7","key":"4091_CR63","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/1078-0432.CCR-18-1981","volume":"25","author":"M Boeri","year":"2019","unstructured":"Boeri M, et al. Circulating MiRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study. Clin Cancer Res. 2019;25(7):2166\u201373.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4091_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70080","volume":"6","author":"L Bi","year":"2025","unstructured":"Bi L, et al. Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis. MedComm. 2025;6(3):e70080.","journal-title":"MedComm"},{"issue":"34","key":"4091_CR65","doi-asserted-by":"publisher","first-page":"35183","DOI":"10.18632\/oncotarget.5930","volume":"6","author":"S Donzelli","year":"2015","unstructured":"Donzelli S, et al. Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget. 2015;6(34):35183\u2013201.","journal-title":"Oncotarget"},{"key":"4091_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.omtn.2022.10.001","volume":"30","author":"KM Pilala","year":"2022","unstructured":"Pilala KM, et al. Epigenetic regulation of MIR145 core promoter controls miR-143\/145 cluster in bladder cancer progression and treatment outcome. Mol Ther Nucleic Acids. 2022;30:311\u201322.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"4091_CR67","first-page":"4617","volume":"35","author":"K Harada","year":"2015","unstructured":"Harada K, et al. Suppressor microRNA-145 is epigenetically regulated by promoter hypermethylation in esophageal squamous cell carcinoma. Anticancer Res. 2015;35(9):4617\u201324.","journal-title":"Anticancer Res"},{"issue":"5","key":"4091_CR68","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/carcin\/bgr036","volume":"32","author":"SO Suh","year":"2011","unstructured":"Suh SO, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 2011;32(5):772\u20138.","journal-title":"Carcinogenesis"},{"issue":"1","key":"4091_CR69","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/0008-5472.CAN-09-2021","volume":"70","author":"M Sachdeva","year":"2010","unstructured":"Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010;70(1):378\u201387.","journal-title":"Cancer Res"},{"issue":"4","key":"4091_CR70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2009.02.038","volume":"137","author":"N Xu","year":"2009","unstructured":"Xu N, et al. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647\u201358.","journal-title":"Cell"},{"key":"4091_CR71","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.omto.2021.07.001","volume":"22","author":"C-G Liu","year":"2021","unstructured":"Liu C-G, et al. Long non-coding RNAs and circular RNAs in tumor angiogenesis: from mechanisms to clinical significance. Mol Therapy - Oncolytics. 2021;22:336\u201354.","journal-title":"Mol Therapy - Oncolytics"},{"issue":"3","key":"4091_CR72","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11523-020-00717-x","volume":"15","author":"M Ratti","year":"2020","unstructured":"Ratti M, et al. MicroRNAs (miRNAs) and long Non-Coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol. 2020;15(3):261\u201378.","journal-title":"Target Oncol"},{"issue":"11","key":"4091_CR73","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3349\/ymj.2019.60.11.1081","volume":"60","author":"C Liu","year":"2019","unstructured":"Liu C, et al. LncRNA MALAT1\/MiR-145 adjusts IL-1\u03b2-induced chondrocytes viability and cartilage matrix degradation by regulating ADAMTS5 in human osteoarthritis. Yonsei Med J. 2019;60(11):1081\u201392.","journal-title":"Yonsei Med J"},{"issue":"6","key":"4091_CR74","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.21037\/tau-20-1526","volume":"10","author":"D Zhang","year":"2021","unstructured":"Zhang D, et al. Long NcRNA MALAT1 promotes cell proliferation, migration, and invasion in prostate cancer via sponging miR-145. Transl Androl Urol. 2021;10(6):2307\u201319.","journal-title":"Transl Androl Urol"},{"issue":"10","key":"4091_CR75","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/1759-7714.15257","volume":"15","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, et al. CircCPA4 induces ASCT2 expression to promote tumor property of non-small cell lung cancer cells in a miR-145-5p-dependent manner. Thorac Cancer. 2024;15(10):764\u201377.","journal-title":"Thorac Cancer"},{"key":"4091_CR76","doi-asserted-by":"publisher","first-page":"109828","DOI":"10.1016\/j.biopha.2020.109828","volume":"124","author":"F Zheng","year":"2020","unstructured":"Zheng F, Xu R. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p\/ABCC1 axis. Biomed Pharmacother. 2020;124:109828.","journal-title":"Biomed Pharmacother"},{"key":"4091_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204910","author":"R Charkiewicz","year":"2023","unstructured":"Charkiewicz R, et al. Serum insights: leveraging the power of miRNA profiling as an early diagnostic tool for non-small cell lung cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15204910.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4091_CR78","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/cr.2008.282","volume":"18","author":"X Chen","year":"2008","unstructured":"Chen X, et al. Characterization of micrornas in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997\u20131006.","journal-title":"Cell Res"},{"issue":"3","key":"4091_CR79","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/carcin\/bgab121","volume":"43","author":"H Li","year":"2022","unstructured":"Li H, et al. MiR-145 modulates the radiosensitivity of non-small cell lung cancer cells by suppression of TMOD3. Carcinogenesis. 2022;43(3):288\u201396.","journal-title":"Carcinogenesis"},{"issue":"4","key":"4091_CR80","doi-asserted-by":"publisher","first-page":"152872","DOI":"10.1016\/j.prp.2020.152872","volume":"216","author":"Q Chen","year":"2020","unstructured":"Chen Q, et al. miR-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3. Pathol Res Pract. 2020;216(4):152872.","journal-title":"Pathol Res Pract"},{"key":"4091_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052191","author":"C Antoun","year":"2025","unstructured":"Antoun C, et al. Plasma miR-145-5p levels and risk of future cancer-results from the HUNT study. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26052191.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4091_CR82","first-page":"6739","volume":"11","author":"WX Xu","year":"2019","unstructured":"Xu WX, et al. MiR-145: a potential biomarker of cancer migration and invasion. Am J Transl Res. 2019;11(11):6739\u201353.","journal-title":"Am J Transl Res"},{"issue":"1","key":"4091_CR83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12885-024-11830-9","volume":"24","author":"M Yan","year":"2024","unstructured":"Yan M, et al. Prognostic value of plasma MicroRNAs for non-small cell lung cancer based on data mining models. BMC Cancer. 2024;24(1):52.","journal-title":"BMC Cancer"},{"issue":"10","key":"4091_CR84","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.clinbiochem.2013.02.015","volume":"46","author":"N Becker","year":"2013","unstructured":"Becker N, Lockwood CM. Pre-analytical variables in MiRNA analysis. Clin Biochem. 2013;46(10):861\u20138.","journal-title":"Clin Biochem"},{"key":"4091_CR85","doi-asserted-by":"publisher","first-page":"p731479","DOI":"10.1155\/2015\/731479","volume":"2015","author":"P Tiberio","year":"2015","unstructured":"Tiberio P, et al. Challenges in using Circulating MiRNAs as cancer biomarkers. Biomed Res Int. 2015;2015:p731479.","journal-title":"Biomed Res Int"},{"issue":"2","key":"4091_CR86","doi-asserted-by":"publisher","first-page":"020501","DOI":"10.11613\/BM.2024.020501","volume":"34","author":"M Zendjabil","year":"2024","unstructured":"Zendjabil M. Preanalytical, analytical and postanalytical considerations in Circulating MicroRNAs measurement. Biochem Med (Zagreb). 2024;34(2):020501.","journal-title":"Biochem Med (Zagreb)"},{"issue":"3","key":"4091_CR87","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.lungcan.2013.05.007","volume":"81","author":"A Markou","year":"2013","unstructured":"Markou A, et al. Clinical evaluation of MicroRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013;81(3):388\u201396.","journal-title":"Lung Cancer"},{"key":"4091_CR88","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1471-2407-6-200","volume":"6","author":"S Saviozzi","year":"2006","unstructured":"Saviozzi S, et al. Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer. BMC Cancer. 2006;6:200.","journal-title":"BMC Cancer"},{"key":"4091_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184353","author":"S Donati","year":"2019","unstructured":"Donati S, Ciuffi S, Brandi ML. Human circulating miRNAs real-time qRT-PCR-based analysis: an overview of endogenous reference genes used for data normalization. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20184353.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4091_CR90","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/JCM.01287-11","volume":"50","author":"RT Hayden","year":"2012","unstructured":"Hayden RT, et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol. 2012;50(2):337\u201345.","journal-title":"J Clin Microbiol"},{"key":"4091_CR91","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1186\/s40064-015-1613-3","volume":"4","author":"Z Liu","year":"2015","unstructured":"Liu Z, et al. Reproducibility of quantitative real-time PCR assay in MicroRNA expression profiling and comparison with microarray analysis in narcolepsy. Springerplus. 2015;4:812.","journal-title":"Springerplus"},{"key":"4091_CR92","first-page":"513","volume":"33","author":"Z Banglin","year":"2021","unstructured":"Banglin Z, et al. Diagnostic value of serum miRNA-145, miRNA-21 and miRNA-197 for non-small cell lung cancer. Cancer Res Clin. 2021;33:513\u20137.","journal-title":"Cancer Res Clin"},{"issue":"2","key":"4091_CR93","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3892\/ol.2016.5462","volume":"13","author":"H Zhang","year":"2017","unstructured":"Zhang H, et al. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett. 2017;13(2):669\u201376.","journal-title":"Oncol Lett"},{"key":"4091_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194774","author":"E Garbo","year":"2023","unstructured":"Garbo E, et al. Exploring the potential of non-coding RNAs as liquid biopsy biomarkers for lung cancer screening: a literature review. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15194774.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4091_CR95","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrc3820","volume":"14","author":"C Alix-Panabi\u00e8res","year":"2014","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623\u201331.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"4091_CR96","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2010.28.7045","volume":"29","author":"MG Krebs","year":"2011","unstructured":"Krebs MG, et al. Evaluation and prognostic significance of Circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29(12):1556\u201363.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4091_CR97","doi-asserted-by":"publisher","first-page":"R118","DOI":"10.1186\/bcr3243","volume":"14","author":"V M\u00fcller","year":"2012","unstructured":"M\u00fcller V, et al. Prognostic impact of circulating tumor cells assessed with the cellsearch System\u2122 and adnatest Breast\u2122 in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012;14(4):R118.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"4091_CR98","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.biotechadv.2018.03.007","volume":"36","author":"S Sharma","year":"2018","unstructured":"Sharma S, et al. Circulating tumor cell isolation, culture, and downstream molecular analysis. Biotechnol Adv. 2018;36(4):1063\u201378.","journal-title":"Biotechnol Adv"},{"issue":"6","key":"4091_CR99","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1470-2045(19)30310-9","volume":"20","author":"K Page","year":"2019","unstructured":"Page K, Shaw JA, Guttery DS. The liquid biopsy: towards standardisation in preparation for prime time. Lancet Oncol. 2019;20(6):758\u201360.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4091_CR100","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-022-00403-2","volume":"10","author":"S Ju","year":"2022","unstructured":"Ju S, et al. Detection of circulating tumor cells: opportunities and challenges. Biomark Res. 2022;10(1):58.","journal-title":"Biomark Res"},{"issue":"6","key":"4091_CR101","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3892\/ol.2014.2016","volume":"7","author":"A Abdallah","year":"2014","unstructured":"Abdallah A, et al. Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer. Oncol Lett. 2014;7(6):2121\u20139.","journal-title":"Oncol Lett"},{"issue":"6","key":"4091_CR102","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/cncr.11529","volume":"98","author":"M Tamura","year":"2003","unstructured":"Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer. 2003;98(6):1217\u201322.","journal-title":"Cancer"},{"issue":"1","key":"4091_CR103","first-page":"765","volume":"8","author":"RJ Wang","year":"2015","unstructured":"Wang RJ, et al. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(1):765\u201371.","journal-title":"Int J Clin Exp Pathol"},{"issue":"55","key":"4091_CR104","doi-asserted-by":"publisher","first-page":"94980","DOI":"10.18632\/oncotarget.21739","volume":"8","author":"F Moretti","year":"2017","unstructured":"Moretti F, et al. Systematic review and critique of circulating MiRNAs as biomarkers of stage I-II non-small cell lung cancer. Oncotarget. 2017;8(55):94980\u201396.","journal-title":"Oncotarget"},{"issue":"1","key":"4091_CR105","doi-asserted-by":"publisher","first-page":"8549","DOI":"10.1038\/s41598-018-26864-w","volume":"8","author":"K Skjefstad","year":"2018","unstructured":"Skjefstad K, et al. A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer. Sci Rep. 2018;8(1):8549.","journal-title":"Sci Rep"},{"issue":"3","key":"4091_CR106","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/15384047.2016.1139242","volume":"17","author":"Y Li","year":"2016","unstructured":"Li Y, et al. Expression levels of microRNA-145 and microRNA-10b are associated with metastasis in non-small cell lung cancer. Cancer Biol Ther. 2016;17(3):272\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"4091_CR107","doi-asserted-by":"publisher","first-page":"101042831769168","DOI":"10.1177\/1010428317691683","volume":"39","author":"TQ Gan","year":"2017","unstructured":"Gan TQ, et al. Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data. Tumour Biol. 2017;39(3):1010428317691683.","journal-title":"Tumour Biol"},{"issue":"3","key":"4091_CR108","first-page":"209","volume":"12","author":"JG Bustamante Alvarez","year":"2015","unstructured":"Bustamante Alvarez JG, et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med. 2015;12(3):209\u201322.","journal-title":"Cancer Biol Med"},{"issue":"5","key":"4091_CR109","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/PPO.0000000000000141","volume":"21","author":"L Du","year":"2015","unstructured":"Du L, Morgensztern D. Chemotherapy for advanced-stage non-small cell lung cancer. Cancer J. 2015;21(5):366\u201370.","journal-title":"Cancer J"},{"issue":"1","key":"4091_CR110","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14737140.2018.1409624","volume":"18","author":"M Nagasaka","year":"2018","unstructured":"Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018;18(1):63\u201370.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4091_CR111","doi-asserted-by":"publisher","first-page":"945102","DOI":"10.3389\/fonc.2022.945102","volume":"12","author":"Q Guo","year":"2022","unstructured":"Guo Q, et al. Current treatments for non-small cell lung cancer. Front Oncol. 2022;12:945102.","journal-title":"Front Oncol"},{"issue":"1","key":"4091_CR112","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-023-01436-2","volume":"16","author":"SM Liu","year":"2023","unstructured":"Liu SM, et al. Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol. 2023;16(1):40.","journal-title":"J Hematol Oncol"},{"key":"4091_CR113","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fonc.2017.00038","volume":"7","author":"B Melosky","year":"2017","unstructured":"Melosky B. Current treatment algorithms for patients with metastatic Non-Small Cell, Non-Squamous lung cancer. Front Oncol. 2017;7:38.","journal-title":"Front Oncol"},{"issue":"6","key":"4091_CR114","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7150\/ijms.75315","volume":"20","author":"S Wang","year":"2023","unstructured":"Wang S, et al. SOX2 promotes radioresistance in Non-small cell lung cancer by regulating tumor cells dedifferentiation. Int J Med Sci. 2023;20(6):781\u201396.","journal-title":"Int J Med Sci"},{"issue":"6","key":"4091_CR115","first-page":"1798","volume":"7","author":"LC Young","year":"2001","unstructured":"Young LC, et al. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001;7(6):1798\u2013804.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4091_CR116","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1096\/fj.201701237RR","volume":"32","author":"Q Lu","year":"2018","unstructured":"Lu Q, et al. Long noncoding RNA SNHG1 promotes non-small cell lung cancer progression by up-regulating MTDH via sponging miR-145-5. Faseb J. 2018;32(7):3957\u201367.","journal-title":"Faseb J"},{"issue":"6","key":"4091_CR117","first-page":"6261","volume":"18","author":"H Zhang","year":"2019","unstructured":"Zhang H, et al. Silencing long intergenic non-coding RNA 00707 enhances cisplatin sensitivity in cisplatin-resistant non-small-cell lung cancer cells by sponging miR-145. Oncol Lett. 2019;18(6):6261\u20138.","journal-title":"Oncol Lett"},{"issue":"12","key":"4091_CR118","doi-asserted-by":"publisher","first-page":"e3384","DOI":"10.1002\/jgm.3384","volume":"23","author":"Z Tuo","year":"2021","unstructured":"Tuo Z, Liang L, Zhou R. LINC00852 is associated with poor prognosis in non-small cell lung cancer patients and its Inhibition suppresses cancer cell proliferation and chemoresistance via the hsa-miR-145-5p\/KLF4 axis. J Gene Med. 2021;23(12):e3384.","journal-title":"J Gene Med"},{"issue":"4","key":"4091_CR119","first-page":"4821","volume":"16","author":"Y Cui","year":"2018","unstructured":"Cui Y, et al. Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer. Oncol Lett. 2018;16(4):4821\u20138.","journal-title":"Oncol Lett"},{"issue":"6","key":"4091_CR120","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.cllc.2015.01.008","volume":"16","author":"J Bar","year":"2015","unstructured":"Bar J, et al. MiR profiling identifies Cyclin-Dependent kinase 6 downregulation as a potential mechanism of acquired cisplatin resistance in Non-Small-Cell lung carcinoma. Clin Lung Cancer. 2015;16(6):e121\u20139.","journal-title":"Clin Lung Cancer"},{"key":"4091_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315352","author":"WW Chang","year":"2022","unstructured":"Chang WW, et al. MiR-145-5p targets Sp1 in non-small cell lung cancer cells and links to BMI1 induced pemetrexed resistance and epithelial-mesenchymal transition. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232315352.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"4091_CR122","doi-asserted-by":"publisher","first-page":"33144","DOI":"10.18632\/oncotarget.16562","volume":"8","author":"Y Pan","year":"2017","unstructured":"Pan Y, et al. Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. Oncotarget. 2017;8(20):33144\u201358.","journal-title":"Oncotarget"},{"issue":"5","key":"4091_CR123","first-page":"2944","volume":"40","author":"B Li","year":"2018","unstructured":"Li B, et al. MicroRNA\u2013145 inhibits migration and induces apoptosis in human non\u2013small cell lung cancer cells through regulation of the EGFR\/PI3K\/AKT signaling pathway. Oncol Rep. 2018;40(5):2944\u201354.","journal-title":"Oncol Rep"},{"issue":"4","key":"4091_CR124","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.3892\/or.2014.3021","volume":"31","author":"YH Guo","year":"2014","unstructured":"Guo YH, et al. Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR\u2013145 through the ERK1\/2 in non-small cell lung cancer. Oncol Rep. 2014;31(4):1940\u20136.","journal-title":"Oncol Rep"},{"issue":"13","key":"4091_CR125","first-page":"5831","volume":"23","author":"Y Wang","year":"2019","unstructured":"Wang Y, Lian YM, Ge CY. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19. Eur Rev Med Pharmacol Sci. 2019;23(13):5831\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"4091_CR126","first-page":"625","volume":"51","author":"C Yu","year":"2021","unstructured":"Yu C, et al. miR-145-5p modulates gefitinib resistance by targeting NRAS and MEST in Non-Small cell lung cancer. Ann Clin Lab Sci. 2021;51(5):625\u201337.","journal-title":"Ann Clin Lab Sci"},{"issue":"6","key":"4091_CR127","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1667\/RR14185.1","volume":"184","author":"P Gong","year":"2015","unstructured":"Gong P, et al. MicroRNA-145 modulates tumor sensitivity to radiation in prostate cancer. Radiat Res. 2015;184(6):630\u20138.","journal-title":"Radiat Res"},{"issue":"3","key":"4091_CR128","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ymthe.2017.12.023","volume":"26","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, et al. miR-145 antagonizes SNAI1-Mediated stemness and radiation resistance in colorectal cancer. Mol Ther. 2018;26(3):744\u201354.","journal-title":"Mol Ther"},{"issue":"14","key":"4091_CR129","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1093\/nar\/gks324","volume":"40","author":"M Sachdeva","year":"2012","unstructured":"Sachdeva M, et al. Negative regulation of miR-145 by C\/EBP-\u03b2 through the Akt pathway in cancer cells. Nucleic Acids Res. 2012;40(14):6683\u201392.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"4091_CR130","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1159\/000484459","volume":"43","author":"Z Wang","year":"2017","unstructured":"Wang Z, et al. MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell lung cancer. Cell Physiol Biochem. 2017;43(6):2505\u201315.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"4091_CR131","first-page":"327","volume":"56","author":"M Wang","year":"2020","unstructured":"Wang M, et al. LncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR\u2013145\/p70S6K1 and p53 pathway. Int J Oncol. 2020;56(1):327\u201336.","journal-title":"Int J Oncol"},{"issue":"6","key":"4091_CR132","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.febslet.2015.01.037","volume":"589","author":"C Ye","year":"2015","unstructured":"Ye C, et al. MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells. FEBS Lett. 2015;589(6):702\u20139.","journal-title":"FEBS Lett"},{"issue":"3","key":"4091_CR133","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/carcin\/bgab121","volume":"43","author":"H Li","year":"2021","unstructured":"Li H, et al. MiR-145 modulates the radiosensitivity of non-small cell lung cancer cells by suppression of TMOD3. Carcinogenesis. 2021;43(3):288\u201396.","journal-title":"Carcinogenesis"},{"key":"4091_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169324","author":"F Kipkeeva","year":"2022","unstructured":"Kipkeeva F, et al. The features of immune checkpoint gene regulation by microRNA in cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23169324.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4091_CR135","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.","journal-title":"Mol Cancer"},{"issue":"2","key":"4091_CR136","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-Approved checkpoint inhibitors and companion diagnostics. Aaps J. 2021;23(2):39.","journal-title":"Aaps J"},{"issue":"1","key":"4091_CR137","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41544-019-0022-0","volume":"1","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Tanno T, Kanellopoulou C. Cancer therapeutic implications of MicroRNAs in the regulation of immune checkpoint blockade. ExRNA. 2019;1(1):19.","journal-title":"ExRNA"},{"issue":"4","key":"4091_CR138","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.humimm.2014.01.006","volume":"75","author":"J Zhu","year":"2014","unstructured":"Zhu J, et al. MiR-20b, -21, and \u2212 130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol. 2014;75(4):348\u201353.","journal-title":"Hum Immunol"},{"issue":"10","key":"4091_CR139","doi-asserted-by":"publisher","first-page":"djx034","DOI":"10.1093\/jnci\/djx034","volume":"109","author":"SB Eichm\u00fcller","year":"2017","unstructured":"Eichm\u00fcller SB, et al. Immune modulatory MicroRNAs involved in tumor attack and tumor immune escape. JNCI: J Natl Cancer Inst. 2017;109(10):djx034.","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"11","key":"4091_CR140","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/biom11111648","volume":"11","author":"M-HT Nguyen","year":"2021","unstructured":"Nguyen M-HT, et al. MiRNA as a modulator of immunotherapy and immune response in melanoma. Biomolecules. 2021;11(11):1648.","journal-title":"Biomolecules"},{"issue":"18","key":"4091_CR141","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1111\/febs.15000","volume":"286","author":"HA Omar","year":"2019","unstructured":"Omar HA, et al. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment. FEBS J. 2019;286(18):3540\u201357.","journal-title":"FEBS J"},{"key":"4091_CR142","doi-asserted-by":"publisher","first-page":"144888","DOI":"10.1016\/j.gene.2020.144888","volume":"754","author":"N Skafi","year":"2020","unstructured":"Skafi N, Fayyad-Kazan M, Badran B. Immunomodulatory role for micrornas: regulation of PD-1\/PD-L1 and CTLA-4 immune checkpoints expression. Gene. 2020;754:144888.","journal-title":"Gene"},{"key":"4091_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00848-8","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, et al. The role of cancer-derived MicroRNAs in cancer immune escape. J Hematol Oncol. 2020;13:1\u201314.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4091_CR144","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41598-023-27415-8","volume":"13","author":"S Hajibabaei","year":"2023","unstructured":"Hajibabaei S, et al. Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression. Sci Rep. 2023;13(1):1003.","journal-title":"Sci Rep"},{"issue":"1","key":"4091_CR145","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/cei.13406","volume":"200","author":"Q Sheng","year":"2020","unstructured":"Sheng Q, et al. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Clin Experimental Immunol. 2020;200(1):45\u201352.","journal-title":"Clin Experimental Immunol"},{"issue":"3","key":"4091_CR146","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/cancers11030349","volume":"11","author":"J Zhu","year":"2019","unstructured":"Zhu J, et al. A feedback loop formed by ATG7\/autophagy, FOXO3a\/miR-145 and PD-L1 regulates stem-like properties and invasion in human bladder cancer. Cancers. 2019;11(3):349.","journal-title":"Cancers"},{"issue":"30","key":"4091_CR147","doi-asserted-by":"publisher","first-page":"10277","DOI":"10.1073\/pnas.0805458105","volume":"105","author":"KA Hofmeyer","year":"2008","unstructured":"Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proc Natl Acad Sci USA. 2008;105(30):10277\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"4091_CR148","first-page":"6759","volume":"24","author":"L Huang","year":"2020","unstructured":"Huang L. The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion. Eur Rev Med Pharmacol Sci. 2020;24(12):6759\u201366.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"4091_CR149","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12032-014-0344-6","volume":"32","author":"M Wang","year":"2014","unstructured":"Wang M, et al. Mir-145 acts as a metastasis suppressor by targeting Metadherin in lung cancer. Med Oncol. 2014;32(1):344.","journal-title":"Med Oncol"},{"issue":"2","key":"4091_CR150","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3892\/ol.2014.2231","volume":"8","author":"Y Huang","year":"2014","unstructured":"Huang Y, Li LP. Progress of cancer research on astrocyte elevated gene-1\/Metadherin (Review). Oncol Lett. 2014;8(2):493\u2013501.","journal-title":"Oncol Lett"},{"key":"4091_CR151","doi-asserted-by":"publisher","first-page":"783860","DOI":"10.3389\/fonc.2021.783860","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Golgi phosphoprotein 73: the driver of Epithelial-Mesenchymal transition in cancer. Front Oncol. 2021;11:783860.","journal-title":"Front Oncol"},{"key":"4091_CR152","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.biopha.2018.01.161","volume":"99","author":"L Yang","year":"2018","unstructured":"Yang L, et al. DNMT1\/miR-200a\/GOLM1 signaling pathway regulates lung adenocarcinoma cells proliferation. Biomed Pharmacother. 2018;99:839\u201347.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4091_CR153","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ccell.2016.07.017","volume":"30","author":"QH Ye","year":"2016","unstructured":"Ye QH, et al. GOLM1 modulates EGFR\/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell. 2016;30(3):444\u201358.","journal-title":"Cancer Cell"},{"issue":"9","key":"4091_CR154","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nrm2476","volume":"9","author":"SJ Heasman","year":"2008","unstructured":"Heasman SJ, Ridley AJ. Mammalian rho gtpases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008;9(9):690\u2013701.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"4091_CR155","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3892\/or.2016.4634","volume":"35","author":"W Zhang","year":"2016","unstructured":"Zhang W, Liang Z, Li J. Inhibition of rhotekin exhibits antitumor effects in lung cancer cells. Oncol Rep. 2016;35(5):2529\u201334.","journal-title":"Oncol Rep"},{"issue":"17","key":"4091_CR156","first-page":"5481","volume":"50","author":"AF Gazdar","year":"1990","unstructured":"Gazdar AF, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 1990;50(17):5481\u20137.","journal-title":"Cancer Res"},{"issue":"3","key":"4091_CR157","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/epr.09.17","volume":"6","author":"RJ Simpson","year":"2009","unstructured":"Simpson RJ, et al. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteom. 2009;6(3):267\u201383.","journal-title":"Expert Rev Proteom"},{"key":"4091_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112680","author":"S Reda El Sayed","year":"2021","unstructured":"Reda El Sayed S, et al. MicroRNA therapeutics in cancer: current advances and challenges. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13112680.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4091_CR159","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/17460441.2020.1765770","volume":"15","author":"M Segal","year":"2020","unstructured":"Segal M, Slack FJ. Challenges identifying efficacious MiRNA therapeutics for cancer. Expert Opin Drug Discov. 2020;15(9):987\u201392.","journal-title":"Expert Opin Drug Discov"},{"issue":"15","key":"4091_CR160","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1080\/17435889.2024.2348438","volume":"19","author":"S Dhingra","year":"2024","unstructured":"Dhingra S, et al. Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management. Nanomed (Lond). 2024;19(15):1331\u201346.","journal-title":"Nanomed (Lond)"},{"issue":"2","key":"4091_CR161","doi-asserted-by":"publisher","first-page":"517","DOI":"10.7314\/APJCP.2014.15.2.517","volume":"15","author":"ST Mirakabad","year":"2014","unstructured":"Mirakabad ST. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15(2):517\u201335.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4091_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050958","author":"E Salas-Huenuleo","year":"2022","unstructured":"Salas-Huenuleo E, et al. Peptide targeted gold nanoplatform carrying miR-145 induces antitumoral effects in ovarian cancer cells. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14050958.","journal-title":"Pharmaceutics"},{"issue":"8","key":"4091_CR163","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.nano.2013.05.007","volume":"9","author":"SH Hsu","year":"2013","unstructured":"Hsu SH, et al. Cationic lipid nanoparticles for therapeutic delivery of SiRNA and MiRNA to murine liver tumor. Nanomedicine. 2013;9(8):1169\u201380.","journal-title":"Nanomedicine"},{"issue":"9","key":"4091_CR164","doi-asserted-by":"publisher","first-page":"591","DOI":"10.4155\/tde-2020-0052","volume":"11","author":"W He","year":"2020","unstructured":"He W, et al. Progress in systemic co-delivery of MicroRNAs and chemotherapeutics for cancer treatment by using lipid-based nanoparticles. Ther Deliv. 2020;11(9):591\u2013603.","journal-title":"Ther Deliv"},{"key":"4091_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111901","author":"FC Moraes","year":"2021","unstructured":"Moraes FC, et al. MiRNA delivery by nanosystems: state of the art and perspectives. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13111901.","journal-title":"Pharmaceutics"},{"key":"4091_CR166","doi-asserted-by":"publisher","first-page":"1208547","DOI":"10.3389\/fbioe.2023.1208547","volume":"11","author":"LA Bravo-V\u00e1zquez","year":"2023","unstructured":"Bravo-V\u00e1zquez LA, et al. Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives. Front Bioeng Biotechnol. 2023;11:1208547.","journal-title":"Front Bioeng Biotechnol"},{"issue":"8","key":"4091_CR167","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"H Yin","year":"2014","unstructured":"Yin H, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541\u201355.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"4091_CR168","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-024-02215-4","volume":"24","author":"J Li","year":"2025","unstructured":"Li J, Wang J, Chen Z. Emerging role of exosomes in cancer therapy: progress and challenges. Mol Cancer. 2025;24(1):13.","journal-title":"Mol Cancer"},{"issue":"23","key":"4091_CR169","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1039\/D4NA00501E","volume":"6","author":"SS Palakurthi","year":"2024","unstructured":"Palakurthi SS, et al. A comprehensive review of challenges and advances in exosome-based drug delivery systems. Nanoscale Adv. 2024;6(23):5803\u201326.","journal-title":"Nanoscale Adv"},{"key":"4091_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020598","author":"Y Lu","year":"2023","unstructured":"Lu Y, et al. Exosome-based carrier for RNA delivery: progress and challenges. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15020598.","journal-title":"Pharmaceutics"},{"key":"4091_CR171","doi-asserted-by":"publisher","first-page":"1093607","DOI":"10.3389\/fimmu.2022.1093607","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, et al. Exosomes as smart drug delivery vehicles for cancer immunotherapy. Front Immunol. 2022;13:1093607.","journal-title":"Front Immunol"},{"key":"4091_CR172","doi-asserted-by":"publisher","first-page":"102667","DOI":"10.1016\/j.nano.2023.102667","volume":"50","author":"S Ellipilli","year":"2023","unstructured":"Ellipilli S, et al. Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression. Nanomedicine. 2023;50:102667.","journal-title":"Nanomedicine"},{"issue":"10","key":"4091_CR173","doi-asserted-by":"publisher","first-page":"293","DOI":"10.31083\/j.fbl2710293","volume":"27","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Exosomes as anticancer drug delivery vehicles: prospects and challenges. Front Biosci (Landmark Ed). 2022;27(10):293.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"4091_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174330","author":"A Sand\u00faa","year":"2021","unstructured":"Sand\u00faa A, Alegre E, Gonz\u00e1lez \u00c1. Exosomes in lung cancer: actors and heralds of tumor development. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13174330.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4091_CR175","doi-asserted-by":"publisher","first-page":"17802","DOI":"10.1021\/acsnano.2c08774","volume":"16","author":"R Tenchov","year":"2022","unstructured":"Tenchov R, et al. ExosomesNature\u2019s lipid Nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano. 2022;16(11):17802\u201346.","journal-title":"ACS Nano"},{"key":"4091_CR176","doi-asserted-by":"publisher","first-page":"1471476","DOI":"10.3389\/fphar.2024.1471476","volume":"15","author":"J Fang","year":"2024","unstructured":"Fang J, et al. Role of exosomes in modulating non-small cell lung cancer radiosensitivity. Front Pharmacol. 2024;15:1471476.","journal-title":"Front Pharmacol"},{"key":"4091_CR177","doi-asserted-by":"publisher","first-page":"p6692544","DOI":"10.1155\/2021\/6692544","volume":"2021","author":"S Fan","year":"2021","unstructured":"Fan S, Chen P, Li S. miR-145-5p inhibits the Proliferation, Migration, and invasion of esophageal carcinoma cells by targeting ABRACL. Biomed Res Int. 2021;2021:p6692544.","journal-title":"Biomed Res Int"},{"key":"4091_CR178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091833","author":"LL Mei","year":"2017","unstructured":"Mei LL, et al. MiR-145-5p suppresses tumor cell migration, invasion and epithelial to mesenchymal transition by regulating the Sp1\/NF-\u03baB signaling pathway in esophageal squamous cell carcinoma. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18091833.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4091_CR179","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1002\/ctm2.464","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang L, et al. c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p\/SPOP\/PD-L1 axis. Clin Transl Med. 2021;11(9):e464.","journal-title":"Clin Transl Med"},{"key":"4091_CR180","doi-asserted-by":"crossref","unstructured":"Cheng X et al. mir-145-5p is a suppressor of colorectal cancer at early stage, while promotes colorectal cancer metastasis at late stage through regulating AKT signaling evoked EMT-mediated anoikis. BMC Cancer, 2022. 22(1): p. 1151.","DOI":"10.1186\/s12885-022-10182-6"},{"issue":"1","key":"4091_CR181","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1530\/VB-20-0012","volume":"2","author":"D Sawant","year":"2020","unstructured":"Sawant D, Lilly B. MicroRNA-145 targets in cancer and the cardiovascular system: evidence for common signaling pathways. Vasc Biol. 2020;2(1):R115\u201328.","journal-title":"Vasc Biol"},{"issue":"9","key":"4091_CR182","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1111\/cas.14517","volume":"111","author":"W Xu","year":"2020","unstructured":"Xu W, et al. MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. Cancer Sci. 2020;111(9):3122\u201331.","journal-title":"Cancer Sci"},{"key":"4091_CR183","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biopha.2018.10.037","volume":"109","author":"T Zeinali","year":"2019","unstructured":"Zeinali T, et al. Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomed Pharmacother. 2019;109:195\u2013207.","journal-title":"Biomed Pharmacother"},{"key":"4091_CR184","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113097","author":"MY Momin","year":"2021","unstructured":"Momin MY, et al. The challenges and opportunities in the development of microRNA therapeutics: a multidisciplinary viewpoint. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10113097.","journal-title":"Cells"},{"issue":"1","key":"4091_CR185","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.apsb.2024.09.009","volume":"15","author":"MS Attia","year":"2025","unstructured":"Attia MS, et al. Advances and prospects of RNA delivery nanoplatforms for cancer therapy. Acta Pharm Sinica B. 2025;15(1):52\u201396.","journal-title":"Acta Pharm Sinica B"},{"key":"4091_CR186","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010106","author":"AA Halwani","year":"2022","unstructured":"Halwani AA. Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14010106.","journal-title":"Pharmaceutics"},{"issue":"10","key":"4091_CR187","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.3390\/ijms26104835","volume":"26","author":"J Wu","year":"2025","unstructured":"Wu J, et al. Extracellular Vesicle-Based drug delivery systems in cancer therapy. Int J Mol Sci. 2025;26(10):4835.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4091_CR188","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3892\/br.2014.260","volume":"2","author":"K Murakami","year":"2014","unstructured":"Murakami K, Miyagishi M. Tiny masking locked nucleic acids effectively bind to mRNA and inhibit binding of MicroRNAs in relation to thermodynamic stability. Biomed Rep. 2014;2(4):509\u201312.","journal-title":"Biomed Rep"},{"key":"4091_CR189","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s11658-019-0196-3","volume":"24","author":"R Bartoszewski","year":"2019","unstructured":"Bartoszewski R, Sikorski AF. Editorial focus: understanding off-target effects as the key to successful RNAi therapy. Cell Mol Biol Lett. 2019;24:69.","journal-title":"Cell Mol Biol Lett"},{"key":"4091_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26144231","author":"D Bila","year":"2021","unstructured":"Bila D, et al. The recognition of and reactions to nucleic acid nanoparticles by human immune cells. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26144231.","journal-title":"Molecules"},{"key":"4091_CR191","doi-asserted-by":"crossref","unstructured":"Guo S et al. Emerging frontiers in MicroRNA technology: innovations driving precision medicine. Biomaterials, 2025: p. 123716.","DOI":"10.1016\/j.biomaterials.2025.123716"},{"key":"4091_CR192","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopha.2014.12.019","volume":"69","author":"H Shen","year":"2015","unstructured":"Shen H, et al. Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. Biomed Pharmacother. 2015;69:301\u20135.","journal-title":"Biomed Pharmacother"},{"key":"4091_CR193","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3233\/CBM-150475","volume":"15","author":"S-L Dai","year":"2015","unstructured":"Dai S-L, et al. Prognostic value of microRNA-145 in patients with various cancers: a meta-analysis. Cancer Biomark. 2015;15:507\u201313.","journal-title":"Cancer Biomark"},{"issue":"5","key":"4091_CR194","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1158\/1055-9965.EPI-18-0570","volume":"28","author":"L Xu","year":"2019","unstructured":"Xu L, et al. The prognostic value and regulatory mechanisms of microRNA-145 in various tumors: A systematic review and Meta-analysis of 50 studies. Cancer Epidemiol Biomarkers Prev. 2019;28(5):867\u201381.","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04091-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-04091-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04091-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:11:14Z","timestamp":1768342274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-025-04091-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":194,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4091"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-04091-4","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}